Bausch Health reported its Q3 earnings last week, which showed a 7 percent decrease in overall revenue for the Bausch + Lomb/International segment over the same period last year, due to discontinuations and divestitures. But organic revenue grew by 3 percent (this figure excludes discontinuations, divestitures and foreign exchange impacts) thanks to increased production volumes across the segment.